Olympus (7733) 44th Annual J.P. Morgan Healthcare Conference summary

Market trends and growth opportunities

• Global endoscopy demand is rising at 5% annually, driven by aging populations, increased cancer prevalence, and chronic diseases, with potential for significant expansion as care becomes more accessible globally.

• Expansion opportunities exist in underserved geographies and adjacent disease areas, with potential to triple global procedures if utilization matches leading regions.

• Patients and healthcare stakeholders demand earlier detection, less invasive care, same-visit diagnosis and treatment, and more efficient solutions.

• Olympus aims to leverage its global presence, clinical relationships, and large install base to deliver an adaptive, integrated ecosystem combining imaging, devices, digital solutions, and AI.

• The company’s purpose is to extend and enhance life by pushing the boundaries of medicine and technology.

Strategic imperatives and operational plans

• Three strategic pillars—innovation-driven growth, simplicity, and accountability—underpin the vision for sustainable growth.

• Short-term restructuring and long-term structural changes aim to improve operational efficiency and reach MedTech benchmark cost levels.

• Financial targets include 3-5% annual revenue growth, >10% EPS CAGR from FY2026, and ~100 basis points of operating margin expansion.

• Product launches and portfolio expansion are prioritized in core markets, with a focus on GI, respiratory, urology, and region-specific rollouts.

• High-growth adjacencies and partnerships, such as MacroLux, Gore, and Swan EndoSurgical, support innovation and market expansion.

Technology, AI, and robotics

• OLYSENSE, the AI-powered ecosystem, is designed to standardize procedures, enhance workflow, and improve disease detection, with growing adoption targets through FY 2031.

• Launching advanced endoscopes, single-use devices, and AI-powered solutions like OLYSENSE CAD/AI.

• Endoluminal robotics and co-founded Swan EndoSurgical are top priorities, targeting a $2B GI robotics market by 2040.

• The integrated approach of seeing, reaching, and treating underpins ongoing investments in optics, AI, robotics, and therapeutic portfolios.